EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
05/14/2025
Back to search
Official data from USPTO
ELLIPSES PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ELLIPSES PHARMA
ST13
US500000088490321Class
5, 10, 42, 44
Filing
88490321
Registration
6592661
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
52
Latest update
05/21/2025
Trademark type
Word
Nice classes
5, 10, 42, 44
Filing date
06/26/2019
Registration date
12/21/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/21/2021
Last transaction
05/21/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
99
Owner location
London, GB
Examiner
OJEYEMI, ASHLEY
Law office
O10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Ellipses Pharma Ltd
Representatives
John C. Cain Munck Wilson Mandala, LLP
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancerantibodiesnon-antibody proteinsblood and blood componentsstem cellshormonesblood factorstumour necrosis factors; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; all of the aforesaid for use in oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer
Class 10
Medical and surgical apparatus and instrumentsinstruments for diagnosing and treating cancer; medical analysis devicesmedical diagnostic devices for analyzing the presence or extent of cancerfor monitoring cancer treatmentsimmunotherapy cancer treatmentsradiation therapy cancer treatmentschemotherapy cancer treatmentsradiotherapy cancer treatmentstargeted cancer therapy treatments in the bodyfor analyzing the efficacy of cancer treatments; medical imaging apparatusdevices for cancer imaging; medical scanning apparatus namelydevices for scanning for cancer; apparatus for the diagnosis of cancer; apparatus for use in medical analysis for the diagnosis and treatment of cancer; cell counting units for medical diagnostic useelectrical resistance cell countersflow cytometersmicroscopic image analyzers; diagnostic apparatus for medical use for testing cancer cells; all of the aforesaid for use in oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer
Class 42
Medical and pharmacological research services; biological researchclinical research in the field of cancer and medical research; Providing an on-line network environment featuring technology that enables users to share data for drug and pharmaceutical research and development; Providing an on-line network environment featuring technology that enables users to share data in the field of the designdevelopment and testing of drugs and pharmaceuticals; Providing scientific and technological servicesscientific researchanalysisdesign relating to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer; designdevelopment and testing of drugs and pharmaceuticals for the treatment and/or prevention of cancer; laboratory research into new drugs and pharmaceutical products; pharmaceutical drug development services; research relating into medicines; consultancy services relating to scientific and medical research in the field of cancer and oncology; expert advice relating to drug developmentnamely consulting services in the field of drug development; laboratory analysis in the field of oncology; computer hardware and software design and development in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; computer network services namely providing search engines for obtaining information on a global computer network in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; software hosting serviceshosting software for use by others for use in relation to medical databases and informationin relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; software as a service (SAAS) namelyhosting software for use by others for use in relation to medical databases and informationin relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; Information Technology (IT) consultancyadvisory and information services relating to a network of medical research professionals in the technology field of medical information networks and databases; scientific advisory servicesproviding scientific informationadvice and consultancy in the field of oncology and cancer clinical trials; scientific research projects and studies in the fields of oncology and clinical trials research; conducting clinical trials for others; clinical research in the field of oncology; clinical research in the field of cancer treatments and pharmaceuticals; providing an online network that features technology that enables users to share data for clinical trials; conducting and compiling data for others for research purposes in the field of treatmentcure and prevention of cancer via an online computer network; development of measuring and testing methods in the field of medicine; evaluation of pharmaceutical drug development services of others to assure compliance with industry standards; pharmaceutical product evaluation; pharmaceutical research services; all of the aforesaid in relation to in oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer
Class 44
Medical services; medical consultation services; cancer consultation and treatment servicesmedical diagnosis and treatment of cancer; health care services; health screening services in field of cancer; cancer screening services; managed health care services; pharmaceutical services namelypharmaceutical advice; providing online medical record servicesnamely maintaining personal medical history records and files; advisory and consultancy relating to all of the aforesaid; all of the aforesaid for use in oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer
Publications
History of USPTO decisions and trademark events.
52 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/14/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/14/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/14/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/21/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
11/21/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/21/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/21/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
12/21/2021
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
11/17/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/17/2021
IUCN
NOTICE OF ALLOWANCE CANCELLED
11/03/2021
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
11/03/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/04/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/09/2021
PUBO
PUBLISHED FOR OPPOSITION
03/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/17/2021
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
02/01/2021
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
01/29/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/28/2021
MREI
NOTICE OF REINSTATEMENT E-MAILED
01/15/2021
ZZZY
PREVIOUS ACTION COUNT WITHDRAWN
01/08/2021
RGIA
REINSTATEMENT GRANTED - INADVERTENTLY ABANDONED
01/07/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/07/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/07/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/07/2021
MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
01/07/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/06/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/06/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/06/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/06/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/06/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/21/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/21/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
12/21/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
06/23/2020
GNFR
FINAL REFUSAL E-MAILED
06/23/2020
CNFR
FINAL REFUSAL WRITTEN
06/23/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/03/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/02/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/02/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/02/2019
GNRT
NON-FINAL ACTION E-MAILED
10/02/2019
CNRT
NON-FINAL ACTION WRITTEN
10/02/2019
DOCK
ASSIGNED TO EXAMINER
09/17/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
09/09/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
09/05/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
08/01/2019
ALIE
ASSIGNED TO LIE
07/29/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
07/23/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/06/2019
NWAP
NEW APPLICATION ENTERED
06/29/2019
Continuous trademark protection
Get notified about every new filing that threatens ELLIPSES PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.